WALTHAM, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC:ABOS) (BULLETIN BOARD: ABOS) today announced that it will present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference to be held November 5-7, 2007, at the New York Palace Hotel in New York City. Shawn Cain, Interim President and CEO, Arbios Systems, Inc., will present on Wednesday, November 7th, 2007, at 2:20 p.m. Eastern Time. He will provide a company overview including recent clinical information on the Company's SEPET (TM) Liver Assist Device and the recently announced manufacturing agreements with NxStage Medical, Inc. and Membrana Gmbh. The presentation will be available at: http://www.wsw.com/webcast/rrshq12/abos as a live, audio webcast, then archived afterwards for 90 days. About Arbios' SEPET(TM) Liver Assist Device The SEPET(TM) Liver Assist Device is a sterile, disposable cartridge containing microporous hollow fibers with proprietary permeability characteristics. When a patient's blood is passed through these fibers, blood plasma components of specific molecular weights are expressed through the micropores, thereby cleansing the blood of harmful impurities (e.g., hepatic failure toxins as well as various mediators of inflammation and inhibitors of liver regeneration). These substances would otherwise progressively accumulate in the patient's bloodstream during liver failure, causing hypotension, increasing risk of sepsis development and accelerating damage to the liver, lungs and other organs, including the brain and kidneys, and suppressing the function and regeneration of the liver. SEPET(TM) is designed for use with standard blood dialysis systems available in hospital intensive care units. According to the American Liver Foundation, chronic liver disease is the tenth leading cause of death in the United States, resulting in approximately $10 billion in annual healthcare costs. There is currently no satisfactory therapy available to treat patients in liver failure, other than maintenance and monitoring of vital functions and keeping patients stable through provision of intravenous fluids and blood products, administration of antibiotics and support of vital functions, such as respiration. About Arbios Systems Arbios Systems, Inc. is developing proprietary medical devices and cell- based therapies to enhance the survival of millions of patients each year who experience, or are at risk for, life-threatening episodes of liver failure. The Arbios product candidate portfolio includes the SEPET(TM) Liver Assist Device, a novel blood purification therapy that provides enhanced "liver dialysis," and the HepatAssist(TM) Cell-Based Liver Support System, a bio- artificial liver that combines blood detoxification with liver cell therapy to replace whole liver function in patients with the most severe forms of liver failure. For more information on the Company, please visit http://www.arbios.com/. This press release contains forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to future markets for the Company's products and goals and objectives of the Company's product and clinical development programs. These statements represent the judgment of Arbios' management as of this date and are subject to risks and uncertainties that could materially affect the Company. Arbios cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements. Please refer to our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006, and to our subsequent Quarterly Reports on Form 10-QSB, for a description of risks that may affect our results or business conditions. The Company does not undertake any obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events except as required by law. SEPET(TM) and HepatAssist(TM) are trademarks of Arbios Systems, Inc. DATASOURCE: Arbios Systems, Inc. CONTACT: CONTACT AT ARBIOS: Shawn Cain, Interim President and CEO, +1-781-839-7292, or Scott Hayashi, CFO, +1-626-356-3105, or CONTACT FOR INVESTOR RELATIONS: Lisa Wilson, +1-212-759-3929, or Doug MacDougall +1-508-647-0209 Web site: http://www.arbios.com/

Copyright